Country: Canada
Language: English
Source: Health Canada
ASPARAGINASE
JAZZ PHARMACEUTICALS FRANCE SAS
L01XX02
ASPARAGINASE
10000UNIT
POWDER FOR SOLUTION
ASPARAGINASE 10000UNIT
INTRAMUSCULAR
100
Prescription
ANTINEOPLASTIC AGENTS
Active ingredient group (AIG) number: 0109328001; AHFS:
CANCELLED POST MARKET
2021-07-07
1 PRODUCT MONOGRAPH PR KIDROLASE ® (L-asparaginase) 10,000 IU/Vial Powder for Solution for Intramuscular injection or Intravenous infusion OTHER ANTINEOPLASTIC AGENTS L01XX02 Jazz Pharmaceuticals France SAS 69006 Lyon France Control No. : 227233 Date of Initial Approval: December 31, 1974 Date of Revision: August 12, 2019 2 RECENT MAJOR LABEL CHANGES Part I: Health Professional Information 2. Contraindications Aug, 2019 3. Serious Warnings and Precautions Box Aug, 2019 7. Warnings and Precautions, General Aug, 2019 7. Warnings and Precautions, Endocrine and Metabolism Aug, 2019 7. Warnings and Precautions, Immune Aug, 2019 7. Warnings and Precautions, Special Populations Aug, 2019 8. Adverse Drug Reactions Aug, 2019 3 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ................................................................ 4 1 INDICATIONS ..................................................................................................................... 4 2 CONTRAINDICATIONS ..................................................................................................... 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ......................................................... 4 4 DOSAGE AND ADMINISTRATION ................................................................................... 5 4.1 Dosing Considerations .......................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment ...................................................... 5 4.3 Administration ....................................................................................................... 5 4.4 Reconstitution ....................................................................................................... 6 4.5 Missed Dose ......................................................................................................... 6 5 OVERDOSAGE ................................................................................................................... 6 Read the complete document